Mersana Therapeutics Competitors and Similar CompaniesClear all

Mersana Therapeutics's competitors and similar companies include ADC Therapeutics, Seagen, Salarius Pharmaceuticals and Gliknik.

	Mersana Therapeutics Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.	ADC Therapeutics ADC Therapeutics is a biotechnology company that develops drug conjugates for the treatment of both solid and haematological cancers.	Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.	Salarius Pharmaceuticals Salarius Pharmaceuticals is a clinical-stage biotechnology company developing epigenetic-based cancer treatments.	Gliknik Gliknik is a biopharmaceutical company creating therapies for people living with cancer and immune disorders.
Founding Date	Founding Date 2005	Founding Date 2010	Founding Date 1998	Founding Date 2011	Founding Date 2007
Type	Type Public	Type Public	Type Subsidiary	Type Public	Type Private
Tags	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech drug development healthtech oncology	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy	Tags Healthcare biotech oncology pharma therapy
Locations	Locations Cambridge, US HQ	Locations Epalinges, CH HQ London, GB New Providence, US	Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more	Locations Houston, US HQ	Locations Baltimore, US HQ
Employees	Employees 11033% increase	Employees 1162% increase	Employees 3,25622% increase	Employees 2	Employees 9
Valuation ($)	Valuation ($) 250.3 m	Valuation ($) 295.9 m	Valuation ($) N/A	Valuation ($) 2.4 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $40.5m (FY, 2024)	Revenue (est.) $81.4m (FY, 2025)	Revenue (est.) $2b (FY, 2022)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods $5.1m (FY, 2025)	Cost of goods $410.1m (FY, 2022)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit $76.3m (FY, 2025)	Gross profit $1.6b (FY, 2022)	Gross profit N/A	Gross profit N/A
Net income	Net income ($69.2m) (FY, 2024)	Net income ($142.6m) (FY, 2025)	Net income ($610.3m) (FY, 2022)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 219.5m	Total funding raised $ 526m	Total funding raised $ 164m	Total funding raised N/A	Total funding raised $ 65.1m